Small Cell Lung Cancer Mimicking Pulmonary Tuberculosis in a 22-Year-Old Man: A Diagnostic Challenge in a Tuberculosis-Endemic Setting
DOI:
https://doi.org/10.59890/ijist.v4i8.33Keywords:
Small Cell Lung Cancer, Pulmonary Tuberculosis, Young Adult, Lymphadenopathy, Case Report.Abstract
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy characterized by rapid progression and early metastasis. Its clinical and radiological manifestations may overlap with pulmonary tuberculosis, creating a diagnostic challenge in tuberculosis-endemic settings. This overlap may be particularly misleading in young adults, in whom primary lung malignancy is rarely suspected. Case Presentation: A 22-year-old man presented with a persistent cough, intermittent fever, and an unintentional weight loss of approximately 5–7 kg. Based on his clinical presentation and chest radiographic findings, he was initially diagnosed with clinically presumed pulmonary tuberculosis and received intensive-phase antituberculosis therapy. Despite a slight reduction in cough, his general condition and body weight did not improve. He subsequently developed unilateral cervical lymphadenopathy and swelling of the left cheek, left upper extremity, and both lower extremities. Histopathological examination of a cervical lymph-node biopsy revealed malignant cells, while computed tomography of the chest demonstrated a right lung mass, multiple lymphadenopathies, and pleural effusion. The patient underwent therapeutic thoracentesis, systemic chemotherapy, and supportive care. This case highlights the potential for SCLC to mimic pulmonary tuberculosis, even in a very young patient. Lack of meaningful improvement after empirical antituberculosis treatment, progressive lymphadenopathy, pleural effusion, or clinical deterioration should prompt immediate diagnostic reassessment. Integrating microbiological evaluation, cross-sectional imaging, and timely tissue biopsy is essential to reduce diagnostic delay and facilitate earlier oncological management.
References
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263.
Dingemans, A.-M. C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L. E. L., Lantuejoul, S., Peters, S., Reguart, N., Rudin, C. M., De Ruysscher, D., Van Schil, P. E., & Reck, M. (2021). Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(7), 839–853.
Ganti, A. K. P., Loo, B. W., Bassetti, M., Blakely, C., Chiang, A., D’Amico, T. A., Dilling, T. J., Dowell, J. E., Downey, R. J., Edelman, M. J., Flors, L., Goldsmith, C., Grecula, J. C., Higgins, K. A., Hoffmann, H., Jabbour, S. K., Koczywas, M., Merritt, R. E., Mohindra, N., … Gregory, K. M. (2021). Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 19(12), 1441–1464.
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., Reck, M., Mok, T., Lam, S., Shames, D. S., Liu, J., Ding, B., Lopez-Chavez, A., Kabbinavar, F., Lin, W., … Liu, S. V. (2018). First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. The New England Journal of Medicine, 379(23), 2220–2229.
Liu, B., Liu, H., Li, L., Li, G., & Liu, Y. (2023). Pulmonary Tuberculosis (pp. 169–194).
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., Menzies, D., & Raviglione, M. (2016). Tuberculosis. Nature Reviews Disease Primers, 2, Article 16076.
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Voitko, O., Poltoratskiy, A., Ponce Aix, S., Bondarenko, I., Vasselli, J., Shire, N., Jiang, H., & Goldman, J. W. (2019). Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer: A randomised, controlled, open-label, phase 3 trial. The Lancet, 394(10212), 1929–1939.
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021). Small-cell lung cancer. Nature Reviews Disease Primers, 7(1), Article 3.
Wang, S., Zimmermann, S., Parikh, K., Mansfield, A. S., & Adjei, A. A. (2019). Current diagnosis and management of small-cell lung cancer. Mayo Clinic Proceedings, 94(8), 1599–1622.
